Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319912 | 0.85 | PDE4D (0.57) | — | |
| SCHEMBL15988637 | 0.82 | CTNNB1 (0.61) | SMN1; SMN2NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL1493250 | 0.79 | CYP1A2 (1.00) | SMN1; SMN2TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL13142806 | 0.79 | KMT2A (0.62) | SMN1; SMN2NPC1RAB9ATSHRCYP2C9 | |
| SCHEMBL7348772 | 0.79 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9ATSHRCYP1A2 | |
| SCHEMBL9364577 | 0.77 | CYP1A2 (0.96) | SMN1; SMN2TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6059927 | 0.77 | ALDH1A1 (0.51) | SMN1; SMN2NPC1RAB9ATSHRCYP1A2 | |
| SCHEMBL1307991 | 0.76 | TUBB4A (0.55) | SMN1; SMN2NPC1RAB9ATSHRCYP1A2 | |
| SCHEMBL11463561 | 0.76 | KMT2A (0.52) | SMN1; SMN2NPC1RAB9ATSHRCYP1A2 | |
| SCHEMBL19994485 | 0.76 | KMT2A (0.71) | SMN1; SMN2NPC1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266490-B2 | Radioprotector compounds | GEORGETOWN UNIVERSITY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | GEORGETOWN UNIVERSITY (US) | 2015-02-12 | — | — | US | disclosed |
| WO-2013138600-A1 | RADIOPROTECTOR COMPOUNDS | ROSEN ELIOT M (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-1361210-B1 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| CN-1263731-C | Novel therapeutic immunizing agents and their use in reducing cytokine levels | CELGENE CORP (US) | 2006-07-12 | — | — | CN | disclosed |
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1361210-A2 | Novel immunotherapeutic agents and their use in the reduction of cytokine levels | CELGENE CORPORATION (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| CN-1228080-A | Novel therapeutic immunizing agents and their use in reducing cytokine levels | CELGENE CORP (US) | 1999-09-08 | — | — | CN | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0339599-B1 | Process for producing acylaromatic compounds | SUMITOMO CHEMICAL CO (JP) | 1996-08-21 | — | — | EP | disclosed |
| EP-0339599-A2 | Process for producing acylaromatic compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4108997-A | Diuretic [2]benzopyrano[4,3-b]pyridines and process therefor | AYERST, MCKENNA & HARRISON LIMITED (CA) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | SMN1; SMN2 446/4885NPC1 4804/4885RAB9A 4291/4885 |
| US-10266490-B2 | Radioprotector compounds | DDB1, CASP3, BAD | SMN1; SMN2 4260/4885NPC1 1025/4885RAB9A 1448/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | SMN1; SMN2 446/4885NPC1 4804/4885RAB9A 4291/4885 |
| US-20150044293-A1 | RADIOPROTECTOR COMPOUNDS | DDB1, CASP3, BAD | SMN1; SMN2 4260/4885NPC1 1025/4885RAB9A 1448/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | SMN1; SMN2 446/4885NPC1 4804/4885RAB9A 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.